Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 43(2); 2011 > Article
Original Article Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
Su Jin Lee, MD1, Silvia Park, MD1, Hee Kyung Ahn, MD1, Jun Ho Yi, MD1, Eun Yoon Cho, MD2, Jong Mu Sun, MD2, Jeong Eon Lee, MD3, Seok Jin Nam, MD3, Jung-Hyun Yang, MD3, Yeon Hee Park, MD1, Jin Seok Ahn, MD1, Young-Hyuck Im, MD, PhD1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2011;43(2):89-95.
DOI: https://doi.org/10.4143/crt.2011.43.2.89
Published online: June 30, 2011

1Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence: Young-Hyuck Im, MD, PhD. Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea.
Tel: 82-2-3410-3445, Fax: 82-2-3410-1754, imyh00@skku.edu
• Received: August 12, 2010   • Accepted: October 15, 2010

Copyright © 2011 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 14,704 Views
  • 143 Download
  • 68 Crossref
  • 84 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.
  • Materials and Methods
    Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.
  • Results
    The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).
  • Conclusion
    Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
  • Key words: Bone, Neoplasm metastasis, Breast neoplasms, Estrogen receptors, Progesterone receptors, HER2
Bone is the most common site of metastatic recurrence in breast cancer and bone metastases are a major cause of morbidity for patients with metastatic breast cancer (MBC) [1]. Bone represents the first site of metastasis in >50% of patients who fail systematically [2,3]. After Sherry et al. [4,5] reported that MBC confined to the skeletal system is highly responsive to treatment and associated with prolonged survival, the concept of bone-only metastasis as a first site of relapse emerged. Bone-only metastasis means bone metastasis without evidence of any other organ involvement. Although metastatic spread to most end organs occurs by similar mechanisms [6,7], and survival is almost always poor in patients with extensive disease involving multiple organs, bone-only metastasis in breast cancer patients appears to show a relatively good prognosis [2,4,5,8]. For endocrine-sensitive breast cancer, the National Comprehensive Cancer Network (NCCN) guideline recommends endocrine therapy for the management of MBC confined to the bone and soft tissue [9].
One of the most intriguing biological aspects of metastasis is the pattern of organ dissemination [10]. Aggressive tumor cells typically enter the blood stream and reach distant tissues. This dissemination has stereotypical patterns of organ tropism that reflects the heterogeneity of tumor cells and depends on the cancer type. Estrogen receptor (ER)-positive tumors preferentially spread to bone. Recent data supports the view that bone metastasis is associated with the absence of Wnt signaling [11]. Considering that most bone metastases are associated with an indolent disease course and clinical dormancy, these cases may have characteristic clinical features with predominance of dormancy over aggressive metastatic disseminations.
Hence, we undertook this study; 1) to determine the incidence, clinical course, and treatment outcomes for breast cancer patients with of "bone-only metastases"; and 2) to analyze the impact of hormone receptor and human epidermal growth factor receptor 2 (HER2) status on the prognosis of this group.
We retrospectively reviewed the medical records of patients with pathologically-confirmed invasive breast cancer who received palliative management between October 1994 and March 2007 at Samsung Medical Center. Among 968 MBC patients who had distant relapse, 565 (58.4%) had bone metastases. Of the 565, 146 (25.8%) had bone-only metastasis as the first distant site of relapse. Bone-only metastasis was defined as bone metastasis without evidence of involvement of any other organ. The following patient information was obtained from medical records: gender; age; prior treatment; primary treatment after bone metastasis; presence of progression to other metastatic sites; distant relapse-free survival (DRFS); post-relapse overall survival (PR-OS); and PR progression-free survival (PFS).
ER and progesterone receptor (PgR) positivity was defined as an Allred score from 3-8 by immunohistochemistry (IHC) using antibodies to the ER (Immunotech, Paris, France) and PgR (Novocastra, Newcastle, UK). HER2 status was evaluated using an antibody (Dako, Carpinteria, CA) and/or fluorescence in situ hybridization (FISH). Grades 0 and 1 for HER2 by IHC were defined as a negative result, and grade 3 as a positive result. Amplification of HER2 was confirmed by FISH if HER2 was rated 2+ by IHC. All core biopsies from referral institutes were reviewed by experienced pathologists in our institute including IHC staining at the time of initial referral. The pathology reviews for all surgical specimens were done prospectively and comprehensively by experienced pathologists in our institute. Our study protocol was approved by the Institutional Review Board of Samsung Medical Center.
1. Treatments
After documentation of bone metastasis, patients received palliative local and/or systemic treatment. The agents used in hormonal therapy included tamoxifen, goserelin, and aromatase inhibitors (letrozole and anatrozole), according to menopausal status. Systemic chemotherapeutic regimens, including doxorubicin and taxanes, were given at the physician's discretion or the patients' preference. Anti-HER2 therapy with chemotherapy or hormonal therapy was administered for HER2 overexpressing metastatic breast cancer. Bisphosphonate treatment was performed at the physician's discretion, with or without hormonal therapy and/or chemotherapy.
2. Statistical analysis
DRFS was defined as the time from the date of curative surgery of breast cancer to the date of documentation of distant relapse. PR-OS was measured from the date of distant relapse to the date of death or the last follow-up day. PR-PFS was measured from the date of distant relapse to the date of documented disease progression or death. PR-PFS (other distant) was confined to progression to other distant metastasis besides progression to bone metastasis. PFS and OS were defined as the same for all 146 patients with bone-only metastases including 24 patients presented as stage IV at the time of diagnosis.
Clinicopathologic variables were compared between the "bone-only metastasis" group and the "other metastasis" group, and hormone receptor-positive and -negative patients in the bone-only metastasis group using the Pearson chi-square (χ2) test and Fisher's exact test for categorical variables. Survival curves were calculated using the Kaplan-Meier method and compared with other prognostic variables using the log-rank test. A p-value<0.05 was considered significant. A Cox proportional hazards regression model was used to assess the effect of each potential prognostic variable on PR-OS and PR-PFS.
1. Patient characteristics (Fig. 1)
The median duration of follow-up of all 146 patients with bone-only metastases was 75 months (range, 28 to 124 months).
The clinical characteristics of the patients who relapsed with bone metastasis only are summarized in Table 1. The median age was 47 years (range, 18 to 76 years). High nuclear and histologic grades were noted in 24.7% and 26.7%, respectively. Eighty-five percent were ER+ and/or PR+; the rest were HER2+ (8.2%) and triple negative breast cancer (TNBC) (6.8%). Of the 146 patients, 122 (83.6%) relapsed to bone metastasis after surgery; the remaining 24 (16.4%) were initially metastatic. Among the 122 (83.6%) relapsed patients, 91.8% received adjuvant hormonal therapy. Single bone metastasis occurred in 23.3% of the patients. The median number of involved bones was 2 (range, 1 to 5). Extensive bone metastases, defined as≥10 bones being involved with or without bone destruction or soft tissue formation, were demonstrated in 23.3%. The most commonly involved bone was the spine (55.5%). After palliative treatment, common progression sites were bone (73.3%) and lung (19.2%). The progression site was limited to bone in 55.5% of patients. The main treatment modality was hormonal therapy with or without radiation (45.9%). Systemic chemotherapy was administered to 28.1% of patients with or without radiation. Bisphosphonate therapy was administered to 68.5% of patients. The median time of bisphosphonate therapy was 15.6 months (range, 0.7 to 71.9 months). The 5-year survival rate after documentation of bone metastasis for a median follow-up duration of 75 months was 52.3%.
2. Clinical outcomes
HR+ patients had superior, but not statistically significant metastatic OS compared to HER2+ and TNBCs patients (Fig. 2). The median PR-OS of HR+ breast cancer patients was 65 months. Conversely, the median OS of both HER2+ and TNBCs patients was 40 months, respectively (p=0.077).
Comparing the 34 patients with a single bone metastasis to the 112 patients with multiple bone metastases, much better outcomes (in terms of PR-PFS and PR-OS) occurred in patients with single bone metastasis, as expected. Median PR-PFS values for patients with single and multiple bone metastases were 24 and 14 months, respectively (p=0.002) (Fig. 3A). Median PR-OS values for these patients were 79 and 50 months (p=0.005) (Fig. 3B).
3. Clinicopathologic characteristics according to DRFS
We divided patients into two groups according to a DRFS of 36 months in order to characterize metastatic behavior of bony preferences of metastasis in terms of the time of metastasis. There were significant differences in mean age, histologic grade, adjuvant hormonal therapy, and involved bone sites between patients who had a DRFS of ≥36 months and those who had an DRFS<36 months (Table 2). The numbers of patients for each group were 60 and 62, respectively. The mean age was younger in patients with a DRFS <36 months than in patients with a DRFS≥36 months (46 years vs. 50 years, p=0.041 by t-test). More patients with a DRFS≥36 months were HR+ than patients with a DRFS<36 months, but statistical significance was not reached (91.8% vs. 80.0%, p=0.156). Higher histologic grade (54.8% vs. 35.0%, p=0.072) and nuclear grade (50.0% vs. 26.7%, p=0.024) were more common in patients with a DRFS<36 months. The spine was more commonly involved in patients with a DRFS<36 months (62.1% vs. 43.5%, p=0.042). The sternum was not frequently involved in patients with a DRFS <36 months (8.6% vs. 27.4%, p=0.009). Adjuvant hormonal therapy was administered for patients with a DRFS≥36 months more commonly than patients with a DRFS<36 months (80.0% vs. 55.9%, p=0.005). A greater percentage of patients with a DRFS<36 months had liver (25.0% vs. 6.7%, p=0.011) and lung progression (26.7% vs. 11.7%, p=0.037) than patients with a DRFS≥36 months. The 1-year PR-progression free survival rate was 53.8% vs. 62.5%; the 5-year overall survival rate (OSR) was 50.0% vs. 72.6% (p=0.010).
4. Cox regression multivariate analysis for PR-OS (Table 3)
Single bone metastasis was identified as a favorable independent prognostic factor for PR-OS (hazard ratio [HR], 0.280; p=0.003) with a DRFS≥36 months (HR, 0.280; p=0.038). High histologic grade was identified as an unfavorable independent risk factor for PR-OS (HR, 3.211; p=0.005).
Breast cancer with bone-only metastases is thought to be associated with a relatively favorable prognosis compared with breast cancer with other visceral metastatic sites. Clearly, breast cancer preferentially spreads to bone [12,13]. According to Paget's "seed" and "soil" hypothesis, the perceived compatibilities between disseminated cancer cells (the seed) and certain distant sites (the soil) have long influenced the view of the metastatic process [14]. Considering that metastasis is the end product of an evolutionary process involving diverse interactions between cancer cells and their microenvironment, bone metastasis may be a good example to show a favorable outcome with the indolent disease course of breast cancer, even when there is distant metastasis. Recurrence after curative resection and durable remission is not infrequent. In fact, 20-45% of patients with breast cancer relapse years or decades later [15-17]. To address the role of bone as a single distant end organ in the metastatic process of breast cancer, we analyzed late-onset relapse with a DRFS≥36 months separately. According to our results, late-onset relapses after a DRFS≥36 months developed more in the HR+ subgroup with a low histologic grade (Table 2). In addition, these late-onset relapses confined to bone showed an excellent outcome of 72.6% in terms of the 5-year PR-OSR. The objective tumor burden as metastasis proceeds might be the main problem. A pause in progression has to be considered the most likely explanation for the discrepancy between the estimated and observed disease-free periods [18]. To understand this dormancy, cells must be characterized during the dormant state. Given the results that many of the late-onset bone-only metastatic breast cancers progressed to bone with visceral metastasis, bone may provide a good microenvironmental condition to maintain the 'dormant state.'
Traditionally, this 'favorable preference to the bone' in breast cancer is known to have a relationship with the ER [15,19,20]. The rate of late-onset metastasis was significantly higher in ER+ cases. ER+ breast tumors relapse most prominently to the bones over a protracted period [20]. Furthermore, the overall rate of bone metastasis and the rate of late-onset bone metastasis were significantly higher in ER+ cases than in ER- cases [21,22]. This finding is also supported by our data. Most of the breast cancer subtypes in bone-only metastasis were HR+ (Table 2). Recently, some plausible data explaining the relationship between ER and bone metastases has been reported. Specifically, transforming growth factor-β/bone morphogenic proteins have been reported to have a role in bone metastasis together with the epithelium-to-mesenchyme transition [21]. In addition, there is a report that Src selectively promotes bone metastasis in ER+ breast cancers and supports the idea that there is survival of indolent breast cancer cells in bone marrow [19]. Src is the prototypic member of the non-receptor tyrosine kinase family. Src participates in the activation of various downstream pathways through molecular interactions with growth factor receptors (epidermal growth factor receptor and HER2), integrin cell adhesion receptors, steroid hormone receptors, G protein-coupled receptor, focal adhesion kinase, and cytoskeleton components [23]. The importance of these candidate biomarkers is increased by the urgent need for development of new treatment targets as well as for understanding tumor biology. The identification of mechanisms that support the survival of disseminated cancer cells in their host microenvironments has clear implications for improving the treatment of latent metastatic disease. Survival of indolent and latent tumors eventually results in tumor recurrence. Thus, further prolongation of latency or a permanent stop in dormancy can be equated to 'cancer-free' life.
Cleary, this study was limited by its being a retrospective analysis and by the small size of the bone-only metastases group. Despite these drawbacks, our study successfully demonstrated the clinical characteristics and disease course of bone-only metastases in breast cancer patients. This is from a homogeneous cohort from a single institution with a sizable sample and a long follow-up duration.
The bone-only metastases in breast cancer show excellent clinical outcomes, which developed mainly in the HR+ subgroup. A further study to determine how to regulate this indolent tumor behavior is warranted because it would help identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'

Conflict of interest relevant to this article was not reported.

  • 1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588–1594. PMID: 9362426ArticlePubMed
  • 2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–66. PMID: 3814476ArticlePubMedPMC
  • 3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33–64. 1PMID: 10200776ArticlePubMed
  • 4. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer. 1986;58:178–182. PMID: 2423224ArticlePubMed
  • 5. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system: an indolent disease. Am J Med. 1986;81:381–386. PMID: 2428242ArticlePubMed
  • 6. Lee YT. Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev. 1985;4:153–172. PMID: 3893684ArticlePubMed
  • 7. Kamby C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Zedeler K, et al. The pattern of metastases in human breast cancer: influence of systemic adjuvant therapy and impact on survival. Acta Oncol. 1988;27:715–719. PMID: 3219223ArticlePubMed
  • 8. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77:336–340. PMID: 9461007ArticlePubMedPMC
  • 9. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122–192. PMID: 19200416ArticlePubMed
  • 10. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8:341–352. PMID: 17440531ArticlePubMed
  • 11. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–3114. PMID: 18451135ArticlePubMed
  • 12. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814–2823. PMID: 19109576ArticlePubMedPMC
  • 13. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 2006;13:1033–1067. PMID: 17158753ArticlePubMed
  • 14. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571–573. Article
  • 15. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91:80–85. PMID: 9890174ArticlePubMed
  • 16. Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, et al. Telomerase activity in disseminated prostate cancer cells. BJU Int. 2006;97:1309–1313. PMID: 16686730ArticlePubMed
  • 17. Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmüller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 2001;166:699–703. PMID: 11458120ArticlePubMed
  • 18. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol. 2001;11:297–306. PMID: 11513565ArticlePubMed
  • 19. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67–78. PMID: 19573813ArticlePubMedPMC
  • 20. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100:7737–7742. PMID: 12808139ArticlePubMedPMC
  • 21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. PMID: 15894097ArticlePubMed
  • 22. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003;78:105–118. PMID: 12611463ArticlePubMed
  • 23. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23:7957–7968. PMID: 15489913ArticlePubMed
Fig. 1
Patient cohort. MBC pts, patients with metastatic breast cancer.
crt-43-89-g001.jpg
Fig. 2
Overall survival (OS) from metastasis according to breast cancer subtypes. Blue line represents OS of hormone receptor (HR)-(+) patients; green line represents OS of human epidermal growth factor receptor 2 (HER2)-(+) patients; red line represents OS of triple negative breast cancer (TNBC) patients.
crt-43-89-g002.jpg
Fig. 3
Progression free survival (PFS) (A) and overall survival (OS) (B) between the patients with single and multiple bone involvement; green line represents survival of patients with single bone metastasis; blue line represents survival of patients with multiple bone metastases.
crt-43-89-g003.jpg
Table 1
Characteristics of 146 bone-only breast cancer patients
Characteristics No. of patiens (%)
Age
 Median (range, yr) 47 (18-76)
Nuclear grade
 I 3/95 (2.1)
 II 56/95 (38.4)
 III 36/95 (24.7)
Histologic grade
 I 6/88 (5.7)
 II 43/88 (29.5)
 III 39/88 (26.7)
Breast cancer subtypes
 HR+ (ER+ and/or PR+) 124 (85.0)
 HER2+ (HER2+/ER-/PR-) 12 (8.2)
 TNBC (ER-/PR-/HER2-) 10 (6.8)
p53 positive 40/118 (27.2)
Stage
 1 15 (10.3)
 2 50 (34.3)
 3 57 (39.0)
 4 24 (16.4)
Adjuvant treatment (n=122)
 Chemotherapy 114 (93.4)
 Radiation therapy 70 (57.3)
 Endocrine therapy 112 (91.8)
Single bone metastasis 34 (23.3)
Median numbers of involved areas 2
Extensive bone metastases 34 (23.3)
Involved bones
 Spine 81 (55.5)
 Pelvis 62 (42.5)
 Rib 53 (36.3)
 Sternum 26 (17.8)
 Femur 26 (17.8)
 Humerus 5 (3.5)
 Clavicle 4 (2.7)
Progression sites
 Multiple bones 107 (73.3)
 Initial metastatic bone-only 81 (55.5)
 Lung 28 (19.2)
 Liver 22 (15.1)
 Lymph nodes 20 (13.7)
 Brain 12 (8.2)
 Pleura 11 (7.5)
Treatment for metastatic diseases (first-line treatment)
 Endocrine therapy 54 (36.9)
 Chemotherapy 27 (18.5)
 Radiation therapy 19 (13.0)
 Radiation therapy+chemotherapy 15 (10.3)
 Radiation therapy+endocrine therapy 13 (8.9)
 Supportive care 12 (8.2)
 Chemotherapy+targeted therapy 6 (4.1)
History of biophosphonate treatment 100 (68.5)
1-yr PFSR 59.4
5-yr OSR 52.7

HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; PFSR, progression free survival rate; OSR, overall survival rate.

Table 2
Comparison of clinicopathologic characteristics according to duration of DRFS for relapsed patients (n=122)
Characteristics DRFS＜36 mo
(n=60) (%)		 DRFS≥36 mo
(n=62) (%)		 p-value
Mean age (±SD) 46 (±11.7) 50 (±11.2) 0.041 (t-test)
Initial stage 3 30 (50.8) 26 (42.6) 0.137
Subtypes (n=121) 0.156
 HR+ (ER+ and/or PR+) 48 (80.0) 57 (91.9)
  HER2+ (ER-/PR-/HER2+) 6 (10.0) 2 (3.2)
  TNBC (ER-/PR-/HER2-) 6 (10.0) 3 (4.9)
Histologic type
  IDC vs. non-IDC 50 (94.3) 50 (90.9) 0.716
Histologic grade (n=82)
  High (Grade 3) 23 (54.8) 14 (35.0) 0.072
Nuclear grade (n=89)
  High (Grade 3) 22 (50.0) 12 (26.7) 0.024
Adjuvant chemotherapy (n=121) 57 (95.0) 56 (91.8) 0.717
Adjuvant endocrine therapy (n=112) 33 (55.0) 48 (77.4) 0.005
Involved bone sites
  Spine 62.1 43.5 0.042
  Pelvis 47.4 32.3 0.092
  Sternum 8.6 27.4 0.009
  Femur 19.0 16.1 0.683
  Humerus 5.2 0 0.110
  Rib 41.4 35.5 0.507
  Skull 8.8 11.5 0.764
  Clavicle 3.3 3.2 0.237
Single bone metastasis 3 (5.0) 31 (50.0) ＜0.0001
 Extensive bone metastasesa) 15 (25.9) 10 (16.1) 0.190
 Skeletal eventsb) 14 (24.1) 7 (11.3) 0.064
Progression sites
  Bone 78.3 71.7 0.399
  Liver 25.0 6.7 0.011
  Lung 26.7 11.7 0.037
  Lymph nodes 11.7 8.3 0.762
  Pleura 13.3 1.7 0.032
  Brain 10.0 6.7 0.743
 1 yr PR-PFSR 53.8 62.5 0.362
 5 yr PR-OSR 50.5 72.6 0.010

DRFS, distant relapse free survival; SD, standard deviation; HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; IDC, invasive ductal carcinoma; PFSR, progression free survival rate; OSR, overall survival rate. a)Extensive bone metastases,≥10 bones involvement with or without bone destruction soft tissue formation, b)Skeletal events, associated with bone metastases as pain, fracture, and limit of motion.

Table 3
Cox-regression multivariate analysis for PR-OS
Significance (p-value) Hazard ratio 95% CI
Lower Upper
DRFS≥36 mo 0.038 0.450 0.211 0.958
Single bone metastasis 0.003 0.280 0.121 0.646
High histological grade 0.005 3.211 1.429 7.217

The other factors that had not revealed any significance were adjusted in this multivariate analysis. PR-OS, post-relapse overall survival; CI, confidence interval; DRFS, distant relapse free survival.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis
      Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad
      Biomedicines.2024; 12(5): 1075.     CrossRef
    • Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways
      Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang
      Phytotherapy Research.2024; 38(6): 2860.     CrossRef
    • Acro metastasis: A rare presentation in a common cancer
      Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour
      Current Problems in Cancer: Case Reports.2024; 14: 100292.     CrossRef
    • Concise review: breast cancer stems cells and their role in metastases
      Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard
      Annals of Medicine & Surgery.2024;[Epub]     CrossRef
    • Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
      Saptarshi Sinha, Brennan W. Callow, Alex P. Farfel, Suchismita Roy, Siyi Chen, Maria Masotti, Shrila Rajendran, Johanna M. Buschhaus, Celia R. Espinoza, Kathryn E. Luker, Pradipta Ghosh, Gary D. Luker
      Journal of Clinical Investigation.2024;[Epub]     CrossRef
    • Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
      Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras
      Current Oncology.2023; 30(2): 1416.     CrossRef
    • Surgery in the Setting of Metastatic Breast Cancer
      Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup
      Current Breast Cancer Reports.2023; 15(1): 37.     CrossRef
    • Team Approach: Management of Pathologic Fractures
      Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach
      JBJS Reviews.2023;[Epub]     CrossRef
    • Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
      Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan
      European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477.     CrossRef
    • Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
      Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk
      BMC Cancer.2023;[Epub]     CrossRef
    • SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches
      Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu
      Cell Research.2023; 33(6): 464.     CrossRef
    • Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
      Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill
      International Journal of Molecular Sciences.2023; 24(10): 8488.     CrossRef
    • Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer
      Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun
      BMC Cancer.2023;[Epub]     CrossRef
    • Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept
      Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo
      Journal of Clinical Medicine.2022; 11(13): 3589.     CrossRef
    • Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis
      Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran
      BioMed Research International.2022;[Epub]     CrossRef
    • Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis
      Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong
      International Journal of Pharmaceutics.2022; 625: 122092.     CrossRef
    • Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
      Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq
      Cancer Management and Research.2022; Volume 14: 2519.     CrossRef
    • Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
      Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng
      Cancers.2022; 14(23): 5727.     CrossRef
    • Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?
      E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse
      Critical Reviews in Oncology/Hematology.2021; 157: 103146.     CrossRef
    • Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
      Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
      European Journal of Cancer.2021; 144: 341.     CrossRef
    • Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone
      Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang
      Translational Oncology.2021; 14(2): 100993.     CrossRef
    • Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis
      Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim
      Bone.2021; 144: 115775.     CrossRef
    • Diagnosis and referral of adults with suspected bony metastases
      Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson
      BMJ.2021; : n98.     CrossRef
    • Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
      Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos
      Cancers.2021; 13(6): 1458.     CrossRef
    • Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
      Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue
      European Journal of Radiology.2021; 141: 109821.     CrossRef
    • Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
      Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser
      The Breast.2021; 58: 173.     CrossRef
    • Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
      Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
      Nature Communications.2021;[Epub]     CrossRef
    • Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
      Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak
      Clinical Breast Cancer.2020; 20(1): e54.     CrossRef
    • Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice
      Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas
      Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113.     CrossRef
    • MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9
      Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu
      Bone.2020; 130: 115139.     CrossRef
    • Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
      Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke
      Clinical Breast Cancer.2020; 20(3): 209.     CrossRef
    • Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
      Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti
      PLOS ONE.2020; 15(4): e0227256.     CrossRef
    • International Framework for Red Flags for Potential Serious Spinal Pathologies
      Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe
      Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350.     CrossRef
    • Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
      Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu
      The Oncologist.2020; 25(8): e1170.     CrossRef
    • Imaging diagnosis of metastatic breast cancer
      Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh
      Insights into Imaging.2020;[Epub]     CrossRef
    • Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells
      Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo
      Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
    • Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
      Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo
      Breast Cancer Research and Treatment.2020; 184(1): 23.     CrossRef
    • Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons
      Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli
      Frontiers in Bioengineering and Biotechnology.2020;[Epub]     CrossRef
    • The influence of breast cancer subtype on survival after palliative radiation for osseous metastases
      Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins
      Cancer Medicine.2020; 9(23): 8979.     CrossRef
    • Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
      Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao
      Breast Cancer Research and Treatment.2019; 173(1): 225.     CrossRef
    • Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study
      Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li
      European Journal of Surgical Oncology.2019; 45(8): 1364.     CrossRef
    • The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis
      Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage
      Nature Communications.2019;[Epub]     CrossRef
    • Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
      Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova
      Clinical Breast Cancer.2018; 18(1): e41.     CrossRef
    • Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
      Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan
      Breast Cancer Research and Treatment.2018; 167(2): 579.     CrossRef
    • Breast cancer bone metastases: pathogenesis and therapeutic targets
      Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan
      The International Journal of Biochemistry & Cell Biology.2018; 96: 63.     CrossRef
    • Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data
      Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu
      Journal of Bone Oncology.2018; 11: 38.     CrossRef
    • Breast osteoblast-like cells: a new biomarker for the management of breast cancer
      Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno
      British Journal of Cancer.2018; 119(9): 1129.     CrossRef
    • Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
      Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
      Breast Cancer.2017; 24(3): 473.     CrossRef
    • Pattern of metastatic spread and subcategories of breast cancer
      Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner
      Archives of Gynecology and Obstetrics.2017; 295(1): 211.     CrossRef
    • Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid
      Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini
      The Breast Journal.2017; 23(5): 610.     CrossRef
    • The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
      Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu
      The Journal of Pathology.2017; 242(1): 73.     CrossRef
    • Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
      I Bado, Z Gugala, S A W Fuqua, X H-F Zhang
      Oncogene.2017; 36(32): 4527.     CrossRef
    • Which red flags aid the early detection of metastatic bone disease in back pain?
      Laura Finucane, Susan Greenhalgh, James Selfe
      Physiotherapy Practice and Research.2017; 38(2): 73.     CrossRef
    • Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
      Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An
      Medicine.2017; 96(50): e8985.     CrossRef
    • Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
      Shinji Ohno
      Clinical Breast Cancer.2016; 16(4): 238.     CrossRef
    • Quality of life and symptom burden in patients with metastatic breast cancer
      Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma
      Supportive Care in Cancer.2016; 24(9): 4035.     CrossRef
    • Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
      Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann
      BMC Cancer.2016;[Epub]     CrossRef
    • Prolactin receptor in breast cancer: marker for metastatic risk
      Carrie S Shemanko
      Journal of Molecular Endocrinology.2016; 57(4): R153.     CrossRef
    • Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers
      Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno
      Clinical Breast Cancer.2015; 15(1): 37.     CrossRef
    • Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer
      Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney
      Clinical Breast Cancer.2015; 15(2): 117.     CrossRef
    • Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
      D.K. Woolf, A.R. Padhani, A. Makris
      Annals of Oncology.2015; 26(6): 1048.     CrossRef
    • Survival time according to the year of recurrence and subtype in recurrent breast cancer
      Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura
      The Breast.2015; 24(5): 588.     CrossRef
    • Cases of Bone-only Metastasis in Recurrent Breast Cancer
      Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA
      Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484.     CrossRef
    • Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
      June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh
      Journal of Breast Cancer.2013; 16(1): 66.     CrossRef
    • Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
      I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons
      Journal of Bone Oncology.2013; 2(4): 137.     CrossRef
    • Zooming in on the schedule of bone-modifying drugs
      Miguel Martin, Sara López-Tarruella
      The Lancet Oncology.2013; 14(7): 575.     CrossRef
    • Bone metastases: assessment, management and treatment options
      Carole Farrell
      British Journal of Nursing.2013; 22(Sup7): S4.     CrossRef
    • Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien
      K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah
      Médecine Nucléaire.2012; 36(10): 574.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
      Cancer Res Treat. 2011;43(2):89-95.   Published online June 30, 2011
      DOI: https://doi.org/10.4143/crt.2011.43.2.89
      Close
    • XML DownloadXML Download
    • 0
    • 1
    • 2
    Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
    Image Image Image
    Fig. 1 Patient cohort. MBC pts, patients with metastatic breast cancer.
    Fig. 2 Overall survival (OS) from metastasis according to breast cancer subtypes. Blue line represents OS of hormone receptor (HR)-(+) patients; green line represents OS of human epidermal growth factor receptor 2 (HER2)-(+) patients; red line represents OS of triple negative breast cancer (TNBC) patients.
    Fig. 3 Progression free survival (PFS) (A) and overall survival (OS) (B) between the patients with single and multiple bone involvement; green line represents survival of patients with single bone metastasis; blue line represents survival of patients with multiple bone metastases.

    Fig. 1

    Fig. 2

    Fig. 3

    Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
    Characteristics No. of patiens (%)
    Age
     Median (range, yr) 47 (18-76)
    Nuclear grade
     I 3/95 (2.1)
     II 56/95 (38.4)
     III 36/95 (24.7)
    Histologic grade
     I 6/88 (5.7)
     II 43/88 (29.5)
     III 39/88 (26.7)
    Breast cancer subtypes
     HR+ (ER+ and/or PR+) 124 (85.0)
     HER2+ (HER2+/ER-/PR-) 12 (8.2)
     TNBC (ER-/PR-/HER2-) 10 (6.8)
    p53 positive 40/118 (27.2)
    Stage
     1 15 (10.3)
     2 50 (34.3)
     3 57 (39.0)
     4 24 (16.4)
    Adjuvant treatment (n=122)
     Chemotherapy 114 (93.4)
     Radiation therapy 70 (57.3)
     Endocrine therapy 112 (91.8)
    Single bone metastasis 34 (23.3)
    Median numbers of involved areas 2
    Extensive bone metastases 34 (23.3)
    Involved bones
     Spine 81 (55.5)
     Pelvis 62 (42.5)
     Rib 53 (36.3)
     Sternum 26 (17.8)
     Femur 26 (17.8)
     Humerus 5 (3.5)
     Clavicle 4 (2.7)
    Progression sites
     Multiple bones 107 (73.3)
     Initial metastatic bone-only 81 (55.5)
     Lung 28 (19.2)
     Liver 22 (15.1)
     Lymph nodes 20 (13.7)
     Brain 12 (8.2)
     Pleura 11 (7.5)
    Treatment for metastatic diseases (first-line treatment)
     Endocrine therapy 54 (36.9)
     Chemotherapy 27 (18.5)
     Radiation therapy 19 (13.0)
     Radiation therapy+chemotherapy 15 (10.3)
     Radiation therapy+endocrine therapy 13 (8.9)
     Supportive care 12 (8.2)
     Chemotherapy+targeted therapy 6 (4.1)
    History of biophosphonate treatment 100 (68.5)
    1-yr PFSR 59.4
    5-yr OSR 52.7
    Characteristics DRFS＜36 mo
    (n=60) (%)    		 DRFS≥36 mo
    (n=62) (%)    		 p-value
    Mean age (±SD) 46 (±11.7) 50 (±11.2) 0.041 (t-test)
    Initial stage 3 30 (50.8) 26 (42.6) 0.137
    Subtypes (n=121) 0.156
     HR+ (ER+ and/or PR+) 48 (80.0) 57 (91.9)
      HER2+ (ER-/PR-/HER2+) 6 (10.0) 2 (3.2)
      TNBC (ER-/PR-/HER2-) 6 (10.0) 3 (4.9)
    Histologic type
      IDC vs. non-IDC 50 (94.3) 50 (90.9) 0.716
    Histologic grade (n=82)
      High (Grade 3) 23 (54.8) 14 (35.0) 0.072
    Nuclear grade (n=89)
      High (Grade 3) 22 (50.0) 12 (26.7) 0.024
    Adjuvant chemotherapy (n=121) 57 (95.0) 56 (91.8) 0.717
    Adjuvant endocrine therapy (n=112) 33 (55.0) 48 (77.4) 0.005
    Involved bone sites
      Spine 62.1 43.5 0.042
      Pelvis 47.4 32.3 0.092
      Sternum 8.6 27.4 0.009
      Femur 19.0 16.1 0.683
      Humerus 5.2 0 0.110
      Rib 41.4 35.5 0.507
      Skull 8.8 11.5 0.764
      Clavicle 3.3 3.2 0.237
    Single bone metastasis 3 (5.0) 31 (50.0) ＜0.0001
     Extensive bone metastasesa) 15 (25.9) 10 (16.1) 0.190
     Skeletal eventsb) 14 (24.1) 7 (11.3) 0.064
    Progression sites
      Bone 78.3 71.7 0.399
      Liver 25.0 6.7 0.011
      Lung 26.7 11.7 0.037
      Lymph nodes 11.7 8.3 0.762
      Pleura 13.3 1.7 0.032
      Brain 10.0 6.7 0.743
     1 yr PR-PFSR 53.8 62.5 0.362
     5 yr PR-OSR 50.5 72.6 0.010
    Significance (p-value) Hazard ratio 95% CI
    Lower Upper
    DRFS≥36 mo 0.038 0.450 0.211 0.958
    Single bone metastasis 0.003 0.280 0.121 0.646
    High histological grade 0.005 3.211 1.429 7.217
    Table 1 Characteristics of 146 bone-only breast cancer patients

    HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; PFSR, progression free survival rate; OSR, overall survival rate.

    Table 2 Comparison of clinicopathologic characteristics according to duration of DRFS for relapsed patients (n=122)

    DRFS, distant relapse free survival; SD, standard deviation; HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; IDC, invasive ductal carcinoma; PFSR, progression free survival rate; OSR, overall survival rate. a)Extensive bone metastases,≥10 bones involvement with or without bone destruction soft tissue formation, b)Skeletal events, associated with bone metastases as pain, fracture, and limit of motion.

    Table 3 Cox-regression multivariate analysis for PR-OS

    The other factors that had not revealed any significance were adjusted in this multivariate analysis. PR-OS, post-relapse overall survival; CI, confidence interval; DRFS, distant relapse free survival.

    Table 1

    Table 2

    Table 3

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP